LY3848575
Phase 2Small molecule
Eli LillyLY3848575 is one of 58 small molecule programs targeting Neuropathic Pain. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
212 competitors in Neuropathic Pain
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaPhase 3
Namenda
AbbViePhase 3
Briviact
UCBPhase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Sativex
Jazz PharmaceuticalsPhase 3
Ultram
WWim Janssens
Phase 3
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Phase 3
Paxil
SSebela Pharmaceuticals Development LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY3848575. EMBL-EBI & Wellcome Sanger Institute.
- [4]